John Libbey Eurotext

Epilepsy and cannabidiol: a guide to treatment Volume 22, issue 1, February 2020

  • [Abuhasira et al., 2018] Abuhasira R., Shbiro L., Landschaft Y. Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. Eur J Intern Med. 2018;49:2-6.
  • [Aizpurua-Olaizola et al., 2016] Aizpurua-Olaizola O., Soydaner U., Öztürk E. Evolution of the cannabinoid and terpene content during the growth of cannabis sativa plants from different chemotypes. J Nat Prod. 2016;79:324-331.
  • [Anciones and Gil-Nagel, 2020] Anciones C., Gil-Nagel A. Adverse effects of cannabinoids. Epileptic Disord. 2020;22:S29-32. Suppl. 1
  • [Bettiol et al., 2019] Bettiol A., Lombardi N., Crescioli G. Galenic preparations of therapeutic cannabis sativa differ in cannabinoids concentration: a quantitative analysis of variability and possible clinical implications. Front Pharmacol. 2019;9:1543.
  • [Bialer et al., 2017] Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia. 2017;58:181-221. 2
  • [Bialer et al., 2018] Bialer M., Johannessen S.I., Koepp M.J. Progress report on new antiepileptic drugs: a summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia. 2018;59:1842-1866.
  • [Blümcke et al., 2019] Blümcke I., Arzimanoglou A., Beniczky S., Wiebe S. Roadmap for a competency-based educational curriculum in epileptology: report of the Epilepsy Education Task Force of the ILAE. Epileptic Disord. 2019;21:129-140.
  • [Bonn-Miller et al., 2017] Bonn-Miller M.O., Loflin M.J.E., Thomas B.F., Marcu J.P., Hyke T., Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318:1708-1709. 17
  • [BPNA, 2018] BPNA. Guidance on the use of cannabis-based products for medicinal use in children and young people with epilepsy. 2018. https://bpna.org.uk/userfiles/BPNA_CBPM_Guidance_Oct2018.pdf.
  • [Brodie and Ben-Menachem, 2018] Brodie M.J., Ben-Menachem E. Cannabinoides for epilepsy: What do we know and where do we go? Epilepsia. 2018;59:291-296.
  • [Calvi et al., 2018] Calvi L., Pentimalli D., Panseri S. Comprehensive quality evaluation of medical Cannabis sativa L. inflorescence and macerated oils based on HS-SPME coupled to GC-MS and LC-HRMS (q-exactive orbitrap®) approach. J Pharm Biomed Anal. 2018;150:208-219.
  • [Carcieri et al., 2018] Carcieri C., Tomasello C., Simiele M. Cannabinoids concentration variability in cannabis olive oil galenic preparations. J Pharm Pharmacol. 2018;70:143-149. 1
  • [Centre for Medicinal Canabis, 2019] Centre for Medicinal Canabis. UK CBD Requires Better Regulation and Reform as Industry Moves Towards Billion Pound Sector Status. 2019. https://www.thecmcuk.org/uk_cbd_requires_better_regulation.
  • [Devinsky et al., 2016] Devinsky O., Marsh E., Friedman D. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270-278. 3
  • [Devinsky et al., 2017] Devinsky O., Cross J.H., Laux L. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011-2020. 21
  • [Devinsky et al., 2018a] Devinsky O., Patel A.D., Thiele E.A. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204-e1211.
  • [Devinsky et al., 2018b] Devinsky O., Patel A.D., Cross J.H. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888-1897. 20
  • [Devinsky et al., 2018c] Devinsky O., Verducci C., Thiele E.A. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131-137.
  • [Devinsky et al., 2019] Devinsky O., Nabbout R., Miller I. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019;60:294-302. 2
  • [Filloux, 2015] Filloux F. Cannabinoids for paediatric epilepsy? Up in smoke or real science? Transl Pediatr. 2015;4:271-282.
  • [Franco and Perucca, 2019] Franco V., Perucca E. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Drugs. 2019;79:1435-1454. 13
  • [Gaston et al., 2017] Gaston T.E., Bebin E.M., Cutter G.R. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586-1592.
  • [Geffrey et al., 2015] Geffrey A.L., Pollack S.F., Bruno P.L., Thiele E.A. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246-1251.
  • [GMC, 2008] GMC. Consent: patients and doctors making decisions together. 2008. https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/consent.
  • [GMC, 2019] GMC. Prescribing unlicensed medicines. 2019. https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/prescribing-and-managing-medicines-and-devices/prescribing-unlicensed-medicines.
  • [Gray and Whalley, 2020] Gray R.A., Whalley B. Working mechanisms of cannabinoids. Epileptic Disord. 2020;22:S10-5. Suppl. 1
  • [Hussain et al., 2015] Hussain S.A., Zhou R., Jacobson C. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138-141.
  • [Johannessen and Johannessen Landmark, 2010] Johannessen S.I., Johannessen Landmark C. Antiepileptic drug interactions: basic principles and clinical implications. Current Neuropharm. 2010;8:254-267.
  • [Johannessen Landmark and Patsalos, 2010] Johannessen Landmark C., Patsalos P.N. Drug interactions involving the new second and third-generation antiepileptic drugs. Exp Rev Neurother. 2010;10:119-140.
  • [Johannessen Landmark and Brandl, 2020] Johannessen Landmark C., Brandl U. Pharmacology and drug interactions of cannabinoids. Epileptic Disord. 2020;22:S16-22. Suppl. 1
  • [Johannessen Landmark et al., 2012] Johannessen Landmark C., Johannessen S.I., Tomson T. Host factors affecting antiepileptic drug delivery: pharmacokinetic variability. Adv Drug Deliv Rev. 2012;64:896-910.
  • [Johannessen Landmark et al., 2016] Johannessen Landmark C., Johannessen S.I., Tomson T. Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring. Epileptic Disord. 2016;18:367-383.
  • [Lagae, 2020] Lagae L. Long-term effects of cannabinoids on development/behavior. Epileptic Disord. 2020;22:S33-37. Suppl. 1
  • [Laux et al., 2019] Laux L.C., Bebin E.M., Checketts D. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Res. 2019;154:13-20.
  • [Maa and Figi, 2014] Maa E., Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55:783-786. 6
  • [Miller et al., 2019] Miller I., Perry S., Saneto R. Cannabidiol (CBD; 10 and 20 mg/kg/day) significantly reduces convulsive seizure frequency in children and adolescents with Dravet syndrome (DS): Results of a dose-ranging, multicenter, randomized, double-blind, placebo-controlled trial (GWPCARE2). Neurology. 2019;93:e532. 5
  • [Morrison et al., 2019] Morrison G., Crockett J., Blakey G., Sommerville K. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8:1009-1031. 8
  • [Nabbout and Thiele, 2020] Nabbout R., Thiele E. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials. Epileptic Disord. 2020;22:S23-8. Suppl. 1
  • [NICE, 2019] NICE. Cannabis-based medicinal products. 2019. https://www.nice.org.uk/guidance/ng144.
  • [Pamplona et al., 2018] Pamplona F.A., da Silva L.R., Coan A.C. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;12:759. 9
  • [Patsalos, 2013a] Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs)-Part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52:927-966.
  • [Patsalos, 2013b] Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs)-Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet. 2013;52:1045-1061. 12
  • [Pavlovic et al., 2018] Pavlovic R., Nenna G., Calvi L. Quality traits of “cannabidiol oils”: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules. 2018;20:5. 2
  • [Pegoraro et al., 2019] Pegoraro C.N., Nutter D., Thevenon M., Ramirez C.L. Chemical profiles of cannabis sativa medicinal oil using different extraction and concentration methods. Nat Prod Res. 2019;12:1-4.
  • [Perucca, 2017] Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017;7:61-76. 2
  • [Porcari et al., 2018] Porcari G.S., Fu C., Doll E.D., Carter E.G., Carson R.P. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center. Epilepsy Behav. 2018;80:240-246.
  • [Porter and Jacobson, 2013] Porter B.E., Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29:574-577. 3
  • [Press et al., 2015] Press C.A., Knupp K.G., Chapman K.E. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49-52.
  • [Rosenberg et al., 2017a] Rosenberg E.C., Patra P.H., Whalley B.J. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav. 2017;70:319-327. Pt B
  • [Rosenberg et al., 2017b] Rosenberg E.C., Louik J., Conway E., Devinsky O., Friedman D. Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia. 2017;58:e96-e100. 8
  • [Russo, 2011] Russo E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163:1344-1364.
  • [Santiago et al., 2019] Santiago M., Sachdev S., Arnold J.C., McGregor I.S., Connor M. Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors. Cannabis Cannabinoid Res. 2019;4:165-176. 3
  • [Schonhofen et al., 2018] Schonhofen P., Bristot I.J., Crippa J.A. Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system. CNS Drugs. 2018;32:697-712. 8
  • [Specchio et al., 2020] Specchio N., Pietrafusa N., Cross H.J. Source of cannabinoids: what is available, what is used, and where does it come from? Epileptic Disord. 2020;22:S1-9. Suppl. 1
  • [Szaflarski et al., 2018] Szaflarski J.P., Bebin E.M., Comi A.M. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59:1540-1548. 8
  • [Thiele et al., 2018] Thiele E.A., Marsh E.D., French J.A. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet. 2018;391:1085-1096. 10125
  • [Thiele et al., 2019a] Thiele E., Marsh E., Mazurkiewicz-Beldzinska M. Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2019;60:419-428. 3
  • [Thiele et al., 2019b] Thiele E, Bebin M, Hari Bhathal H, et al. Cannabidiol (CBD) Treatment in Patients with Seizures Associated with Tuberous Sclerosis Complex: A Randomized, Double-blind, Placebo-Controlled Phase 3 Trial (GWPCARE6). AES meeting, Baltimore 2019.
  • [Tzadok et al., 2016] Tzadok M., Uliel-Siboni S., Linder I. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure. 2016;35:41-44.
  • [Vandrey et al., 2015] Vandrey R., Raber J.C., Raber M.E., Douglass B., Miller C., Bonn-Miller M.O. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313:2491-2493. 24